CD84

Across TCGA pan-cancer cohorts, CD84 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CD84 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CD84 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CD84 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where CD84 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	IV	0.238	0.887	.024	6	view →
PDAC	DFS	Median	All	0.321	0.530	.008	5	view →
LUAD	DFS	Quartile	II,III,IV	0.877	0.486	.013	5	view →
LSCC	OS	Median	II,III,IV	1.000	0.900	.014	3	view →
GBM	DFS	Quartile	All	0.639	0.808	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CD84–CCRCC (DFS)

Open the CCRCC breakdown →